Tags

Type your tag names separated by a space and hit enter

Corallopyronin A - a promising antibiotic for treatment of filariasis.
Int J Med Microbiol. 2014 Jan; 304(1):72-8.IJ

Abstract

Lymphatic filariasis and onchocerciasis are diseases of severe morbidity that affect the poorest of the poor in the world. The diseases are caused by filarial nematodes that are transmitted by mosquitoes or biting blackflies and are endemic to more than 80 countries worldwide, mainly in the tropics and sub-tropics. Current control programs aim to eliminate the diseases by distributing antifilarial drugs. However, the primary effect of the drugs is to kill the microfilariae in the blood or skin, thus preventing uptake by the obligate insect vector. Since the adult worms live 10 years or longer, drug distribution requires many years of treatment, which is a heavy burden on the burgeoning health care systems. Sub-optimal response, possible resistance and inadequate population coverage lessen the chances for successful elimination in all endemic areas. The search for new drugs that could enhance elimination by permanently sterilizing or killing adult worms has identified the Wolbachia intracellular bacteria of filarial nematodes as a target. Depleting the obligate endosymbionts from the worms with doxycycline or rifampicin causes a permanent block in oogenesis, embryogenesis and development, and in slow death of the adult worms. These two antibiotics are suitable for individual drug administration, but caveats exist for their inclusion in broader drug administration programs. Here we review Wolbachia as targets for antifilarial drug discovery and highlight the natural product corallopyronin A as an effective drug that is currently being developed specifically for use against filarial nematodes.

Authors+Show Affiliations

University of Bonn, Institute of Pharmaceutical Biology, Bonn, Germany.University Hospital of Bonn, Institute for Medical Microbiology, Immunology and Parasitology, Bonn, Germany.University of Bonn, Institute of Pharmaceutical Biology, Bonn, Germany.University of Bonn, Institute of Pharmaceutical Biology, Bonn, Germany.University Hospital of Bonn, Institute for Medical Microbiology, Immunology and Parasitology, Bonn, Germany.University Hospital of Bonn, Institute for Medical Microbiology, Immunology and Parasitology, Bonn, Germany. Electronic address: Pfarr@microbiology-bonn.de.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24079981

Citation

Schäberle, Till F., et al. "Corallopyronin a - a Promising Antibiotic for Treatment of Filariasis." International Journal of Medical Microbiology : IJMM, vol. 304, no. 1, 2014, pp. 72-8.
Schäberle TF, Schiefer A, Schmitz A, et al. Corallopyronin A - a promising antibiotic for treatment of filariasis. Int J Med Microbiol. 2014;304(1):72-8.
Schäberle, T. F., Schiefer, A., Schmitz, A., König, G. M., Hoerauf, A., & Pfarr, K. (2014). Corallopyronin A - a promising antibiotic for treatment of filariasis. International Journal of Medical Microbiology : IJMM, 304(1), 72-8. https://doi.org/10.1016/j.ijmm.2013.08.010
Schäberle TF, et al. Corallopyronin a - a Promising Antibiotic for Treatment of Filariasis. Int J Med Microbiol. 2014;304(1):72-8. PubMed PMID: 24079981.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Corallopyronin A - a promising antibiotic for treatment of filariasis. AU - Schäberle,Till F, AU - Schiefer,Andrea, AU - Schmitz,Alexander, AU - König,Gabriele M, AU - Hoerauf,Achim, AU - Pfarr,Kenneth, Y1 - 2013/09/04/ PY - 2013/10/2/entrez PY - 2013/10/2/pubmed PY - 2014/9/16/medline KW - Corallopyronin A KW - Filariasis KW - Myxobacteria KW - RNA polymerase KW - Wolbachia SP - 72 EP - 8 JF - International journal of medical microbiology : IJMM JO - Int J Med Microbiol VL - 304 IS - 1 N2 - Lymphatic filariasis and onchocerciasis are diseases of severe morbidity that affect the poorest of the poor in the world. The diseases are caused by filarial nematodes that are transmitted by mosquitoes or biting blackflies and are endemic to more than 80 countries worldwide, mainly in the tropics and sub-tropics. Current control programs aim to eliminate the diseases by distributing antifilarial drugs. However, the primary effect of the drugs is to kill the microfilariae in the blood or skin, thus preventing uptake by the obligate insect vector. Since the adult worms live 10 years or longer, drug distribution requires many years of treatment, which is a heavy burden on the burgeoning health care systems. Sub-optimal response, possible resistance and inadequate population coverage lessen the chances for successful elimination in all endemic areas. The search for new drugs that could enhance elimination by permanently sterilizing or killing adult worms has identified the Wolbachia intracellular bacteria of filarial nematodes as a target. Depleting the obligate endosymbionts from the worms with doxycycline or rifampicin causes a permanent block in oogenesis, embryogenesis and development, and in slow death of the adult worms. These two antibiotics are suitable for individual drug administration, but caveats exist for their inclusion in broader drug administration programs. Here we review Wolbachia as targets for antifilarial drug discovery and highlight the natural product corallopyronin A as an effective drug that is currently being developed specifically for use against filarial nematodes. SN - 1618-0607 UR - https://www.unboundmedicine.com/medline/citation/24079981/Corallopyronin_A___a_promising_antibiotic_for_treatment_of_filariasis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1438-4221(13)00134-3 DB - PRIME DP - Unbound Medicine ER -